A non-randomised Phase III study to evaluate the effectiveness of Deflazacort in boys with Duchenne muscular dystrophy in improving muscle strength and function and minimising side effects.

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12605000077662

Enrollment

Registered

2005-08-05

Start date

2004-11-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Trial of Deflazacort, a steroid which is not currently commercially available in Australia, for boys with DMD who have failed Prednisone trials

Interventions

12-month trial of Deflazacort vs prednisone given as part of routine clinical care

Study design

Allocation

Non-randomised trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Open (masking not used)

Eligibility

Sex/Gender

All

Age

4 Years to 15 Years

Healthy volunteers

Inclusion criteria

Duchenne muscular dystrophy, walking independently, failed Prednisone.

Exclusion criteria

No exclusion criteria

Outcome results